Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
October 20, 2018 Six months of treatment with trastuzumab is substantially more cost-effective than 12 months of therapy. Reducing the duration of trastuzumab to 6 months for the treatment of HER2-positive early breast cancer is cost-effective, primarily due to lower...20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
October 20, 2018 A 20-year follow-up demonstrated a continued survival benefit with HDCT with HSCT for patients with early breast cancer and at least 9 involved axial lymph nodes. Adjuvant high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant (HSCT)...Talazoparib Improves PROs in BRCA-Positive Triple-Negative Breast Cancer
October 22, 2018 Talazoparib resulted in better patient-reported outcomes compared with chemotherapy among women with TNBC and BRCA mutations in the EMBRACA trial. Talazoparib treatment resulted in better patient-reported outcomes (PROs) compared with...Where Have All the T Cells Gone?
August 14, 2018 New research proposes a novel mechanism for how tumors sidestep the immune system in patients with intracranial tumors. Although T-cell lymphopenia in glioblastoma (GBM) is often attributed to the medications administered to a patient, evidence from...Save 40-80%
Dr. Hillel Harris – Lifestyle Medicine – Nutrition – Exercise
Dr. Joseph Gretzula – Skin Care – Anti-Aging – Health
Recent Comments